Patents by Inventor Reetobrata Basu

Reetobrata Basu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION COMBINATION THERAPY
    Publication number: 20240082362
    Abstract: A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 14, 2024
    Inventors: Richard S. BRODY, Thomas J. ZUPANCIC, Uday SANDBHOR, John J. KOPCHICK, Reetobrata BASU
  • Growth hormone antagonist and anti-cancer composition combination therapy
    Patent number: 11857602
    Abstract: A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: January 2, 2024
    Inventors: Richard S. Brody, Thomas J. Zupancic, Uday Sandbhor, John J. Kopchick, Reetobrata Basu
  • Peptide-based inhibitors of growth hormone action and methods of use thereof
    Patent number: 11820804
    Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NOs: 1-25], or a variant thereof, are described.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 21, 2023
    Assignee: Ohio University
    Inventors: Justin M. Holub, John J. Kopchick, Reetobrata Basu
  • PEPTIDE-BASED INHIBITORS OF GROWTH HORMONE ACTION AND METHODS OF USE THEREOF
    Publication number: 20230085176
    Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NOs: 1-25], or a variant thereof, are described.
    Type: Application
    Filed: November 1, 2022
    Publication date: March 16, 2023
    Applicant: Ohio University
    Inventors: Justin M. Holub, John J. Kopchick, Reetobrata Basu
  • METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS
    Publication number: 20230059413
    Abstract: FSP27 compositions and methods for treating cancers are described.
    Type: Application
    Filed: July 7, 2022
    Publication date: February 23, 2023
    Applicant: Ohio University
    Inventors: John J. Kopchick, Vishwajeet Puri, Vishva Sharma, Reetobrata Basu
  • METHOD OF TREATING CANCER AND METHOD OF SENSITIZING CANCER CELLS TO THE ACTION OF CHEMOTHERAPEUTIC AGENTS VIA GROWTH HORMONE RECEPTOR ANTAGONISTS OR KNOCK DOWN
    Publication number: 20230002775
    Abstract: Various aspects of the present invention relate to a method of treating cancer in a subject having cancer cells, wherein the cancer cells possess at least one growth hormone receptor, and wherein the method includes controlling an action of the growth hormone receptor. In various non-limiting embodiments, controlling an action of the growth hormone receptor may occur via knock down of the growth hormone receptor, or may be caused by inhibiting growth hormone action, such as via the use of antibodies directed against growth hormone or the growth hormone receptor. Methods may also relate to administering an antagonist of the growth hormone receptor, and administering at least one anti-tumor drug in concert with administration of the antagonist. Another aspect may include a method of maintaining an anti-tumor drug in cancer cells of a subject by controlling an action of at least one growth hormone receptor in the cancer cells.
    Type: Application
    Filed: September 13, 2022
    Publication date: January 5, 2023
    Inventors: John J. Kopchick, Reetobrata Basu
  • Peptide-based inhibitors of growth hormone action and methods of use thereof
    Patent number: 11524986
    Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NO: 1], or a variant thereof, are described.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: December 13, 2022
    Assignee: Ohio University
    Inventors: Justin M. Holub, John J. Kopchick, Reetobrata Basu
  • Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
    Patent number: 11473088
    Abstract: Various aspects of the present invention relate to a method of treating cancer in a subject having cancer cells, wherein the cancer cells possess at least one growth hormone receptor, and wherein the method includes controlling an action of the growth hormone receptor. In various non-limiting embodiments, controlling an action of the growth hormone receptor may occur via knock down of the growth hormone receptor, or may be caused by inhibiting growth hormone action, such as via the use of antibodies directed against growth hormone or the growth hormone receptor. Methods may also relate to administering an antagonist of the growth hormone receptor, and administering at least one anti-tumor drug in concert with administration of the antagonist. Another aspect may include a method of maintaining an anti-tumor drug in cancer cells of a subject by controlling an action of at least one growth hormone receptor in the cancer cells.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 18, 2022
    Assignee: Ohio University
    Inventors: John J. Kopchick, Reetobrata Basu
  • Therapeutic pegylated growth hormone antagonists
    Patent number: 11452763
    Abstract: Growth hormone receptor antagonists, comprising human growth hormone receptor antagonist G120K, wherein one amino acid of human growth hormone receptor antagonist G120K has been mutated to cysteine or wherein two amino acids of human growth hormone receptor antagonist G120K have been mutated to cysteine, and wherein the one amino acid mutated to cysteine is T142, and wherein the two amino acids mutated to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K mutant. These growth hormone receptor antagonists are useful in treating diseases or conditions, such as cancer and acromegaly, that are responsive to human growth hormone receptor antagonists.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: September 27, 2022
    Inventors: Richard S. Brody, Thomas J. Zupancic, John J. Kopchick, Reetobrata Basu
  • Methods for treating cancers using fat specific protein 27 (FSP27) compositions
    Patent number: 11426445
    Abstract: FSP27 compositions and methods for treating cancers are described.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: August 30, 2022
    Assignee: Ohio University
    Inventors: John Kopchick, Vishwajeet Puri, Vishva Sharma, Reetobrata Basu
  • GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION COMBINATION THERAPY
    Publication number: 20220040266
    Abstract: A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.
    Type: Application
    Filed: August 25, 2021
    Publication date: February 10, 2022
    Inventors: Richard S. BRODY, Thomas J. ZUPANCIC, Uday SANDBHOR, John J. KOPCHICK, Reetobrata BASU
  • PEPTIDE-BASED INHIBITORS OF GROWTH HORMONE ACTION AND METHODS OF USE THEREOF
    Publication number: 20210122801
    Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NO: 1], or a variant thereof, are described.
    Type: Application
    Filed: July 10, 2019
    Publication date: April 29, 2021
    Applicant: Ohio University
    Inventors: Justin M. Holub, John J. Kopchick, Reetobrata Basu
  • THERAPEUTIC PEGYLATED GROWTH HORMONE ANTAGONISTS
    Publication number: 20200390863
    Abstract: Growth hormone receptor antagonists, comprising human growth hormone receptor antagonist G120K, wherein one amino acid of human growth hormone receptor antagonist G120K has been mutated to cysteine or wherein two amino acids of human growth hormone receptor antagonist G120K have been mutated to cysteine, and wherein the one amino acid mutated to cysteine is T142, and wherein the two amino acids mutated to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K mutant. These growth hormone receptor antagonists are useful in treating diseases or conditions, such as cancer and acromegaly, that are responsive to human growth hormone receptor antagonists.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 17, 2020
    Inventors: Richard S. Brody, Thomas J. Zupancic, John J. Kopchick, Reetobrata Basu
  • METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS
    Publication number: 20200222502
    Abstract: FSP27 compositions and methods for treating cancers are described.
    Type: Application
    Filed: September 17, 2018
    Publication date: July 16, 2020
    Applicant: Ohio University
    Inventors: John Kopchick, Vishwajeet Puri, Vishva Sharma, Reetobrata Basu
  • Method of Treating Cancer and Method of Sensitizing Cancer Cells to the Action of Chemotherapeutic Agents via Growth Hormone Receptor Antagonists or Knock Down
    Publication number: 20190309308
    Abstract: Various aspects of the present invention relate to a method of treating cancer in a subject having cancer cells, wherein the cancer cells possess at least one growth hormone receptor, and wherein the method includes controlling an action of the growth hormone receptor. In various non-limiting embodiments, controlling an action of the growth hormone receptor may occur via knock down of the growth hormone receptor, or may be caused by inhibiting growth hormone action, such as via the use of antibodies directed against growth hormone or the growth hormone receptor. Methods may also relate to administering an antagonist of the growth hormone receptor, and administering at least one anti-tumor drug in concert with administration of the antagonist. Another aspect may include a method of maintaining an anti-tumor drug in cancer cells of a subject by controlling an action of at least one growth hormone receptor in the cancer cells.
    Type: Application
    Filed: December 1, 2017
    Publication date: October 10, 2019
    Inventors: John J. Kopchick, Reetobrata Basu